过去半个世纪中国的肺癌预防和生物标志物指导下的治疗

Lung Cancer Prevention and Biomarker- Guided Treatment in China During the Last Half Century

讲者：复旦大学附属中山医院 白春学教授

过去半个世纪中国的肺癌预防和生物标志物指导下的治疗

Lung Cancer Targeted Therapy: Insights From the Past To Guide the Future

肺癌免疫治疗：即将来临的有哪些？

Immunotherapy for Lung Cancer: What Is on the Horizon?

探索明天：肺癌预防和治疗进展

Exploring Tomorrow: Advancements in the Prevention and Treatment of Lung Cancer

讲者：IASLC首席执行官 Karen Kelly教授

新辅助特瑞普利单抗+化疗治疗可切除的ⅡB~ⅢB期NSCLC的疗效和生物标志物分析

Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC)

讲者：北京大学肿瘤医院 吴楠教授

动态ctDNA-MRD显示局部晚期NSCLC新辅助免疫化疗的病理获益

Dynamic ctDNA-MRD Indicates Pathological Benefits of Additional Neoadjuvant Chemoimmunotherapy Courses for Locally Advanced NSCLC

洛拉替尼诱导治疗ALK阳性局部晚期NSCLC的2期前瞻性试验中期分析（LORIN）

Interim Analysis of A Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)

确定NSCLC患者术后放疗的候选者： 一项多中心研究

Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Multicenter Study

讲者：国家癌症中心 Z. Ma教授

Trilaciclib+化疗和替雷利珠单抗作为晚期鳞状NSCLC一线治疗的2期随机试验

A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC

RB1状态的基因分型鉴定出SCLC转化的EGFR突变肺癌的两种不同亚型

Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation

替雷利珠单抗+化疗作为ⅡB~ⅢC期NSCLC新辅助/辅助治疗的最新无事件生存结果（LungMark研究）

Updated Event-FreeSurvival of Tislelizumab Plus Chemotherapy Asneoadjuvant/Adjuvant Therapyfor Stage IIB-IIIC NSCLC (LungMark Study)

讲者：中山大学肿瘤防治中心 林耀彬教授

转化型小细胞肺癌与广泛期原发性小细胞肺癌的临床结局

Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer

用三联疗法克服NSCLC的免疫治疗耐药：疗效与机制

Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer with a Triple Combination Therapy: Efficacy and Mechanisms

讲者：上海市肺科医院 Y. Xu教授

靶向治疗或化疗新辅助治疗可切除的Ⅱ~ⅢB期EGFR突变肺腺癌：一项4队列研究

Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts

MDT诊断模型中阿美替尼诱导治疗EGFR突变阳性Ⅲ期NSCLC后的MRD指导疗法（APPROACH研究）

MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)

讲者：广东省人民医院 周清教授

EGFR新抗原肽疫苗联合替雷利珠单抗和化疗治疗对EGFR-TKI耐药的晚期NSCLC

EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy